TIME (6/9, Ducharme) reports, “In recent months, a small but growing number of people with Long COVID – the name adopted by those who develop lingering health problems after catching the virus – are experiencing improvements.” Experts “believe somewhere between 10% and 30% of COVID-19 patients develop long-term symptoms, including fatigue, chronic pain, brain fog, shortness of breath and gastrointestinal problems, though the severity of these can vary.” Dr. Federico Cerrone “is a pulmonologist and the co-medical director of Atlantic Health’s COVID Recovery Center in New Jersey, which has treated about 500 Long COVID patients since it opened in October 2020.” Cerrone says, “There seem to be some individual success stories, but I don’t know if I could tell you that one thing fits all. Sometimes it works, and sometimes it doesn’t work. We’ve learned a lot, but there’s still a lot to learn.”

Related Links:

— “Some Patients Are Reporting Long COVID Recoveries—But Experts Still Don’t Fully Understand Why “Jamie Ducharme, TIME, June 9, 2021

Healio (6/9, Gramigna) reports, “Matching patients and therapists based on therapists’ performance strengths may improve mental health care outcomes,” researches concluded in “primary modified intent-to-treat analyses” in which “they included 218 adult outpatients, of whom 67.4% were women and 88.5% were white, treated by 48 therapists.” The study “showed a match effect on reductions in weekly general symptomatic and functional impairment, global distress and domain-specific impairment.” The findings were published online June 9 in JAMA Psychiatry. Psychiatric News (6/9) also covers the study.

Related Links:

— “Patient-therapist matching via therapist’s performance strengths may improve outcomes “Joe Gramigna, Healio, June 9, 2021

HealthDay (6/8, Norton) reports that research suggests “AD/HD medications might help lessen the risk of suicide in children with serious behavioral issues.” Investigators “found that medications like Ritalin [methylphenidate] and Adderall [amphetamine-dextroamphetamine], commonly prescribed for attention-deficit/hyperactivity disorder (AD/HD), were linked to a lower risk of suicidal behavior among 9- and 10-year-olds with substantial ‘externalizing’ symptoms.” The findings were published in JAMA Network Open.

Related Links:

— “ADHD Meds May Help Keep Some Kids From Thoughts of Suicide ” Amy Norton, HealthDay, June 8, 2021

HCPlive (6/8, Walter) reports, “As the COVID-19 pandemic continued, physician visits for individuals with postpartum mental illnesses were significantly higher than what was expected based on prepandemic data,” investigators concluded after comparing “physician visit rates for postpartum mental illness in Ontario during the pandemic with rates that were expected based on prepandemic patterns.” The findingsof the “population-based, repeated cross-sectional study” were published online June 7 in CMAJ.

Related Links:

— “Increase in Postpartum Physician Visits During COVID-19 Pandemic “Kenny Walter, HCPlive, June 8, 2021

MedPage Today (6/7, Kneisel) reports, “Language development scores at age two were similar for children of women with epilepsy taking antiseizure medications and children with healthy mothers,” researchers concluded in an analysis that “included 292 children of women with epilepsy (median age of about 2, 53% girls) and 90 children of healthy women (median age of about 2, 52% boys).” According to the article, “most of the mothers with epilepsy were taking lamotrigine (Lamictal; 46%) or levetiracetam (Keppra; 33.2%),” and “about 45% were taking both.” The findings were published online in JAMA Neurology.

Related Links:

— MedPage Today (requires login and subscription)